Get access

The MECP2 duplication syndrome


  • The content is solely the responsibility of the authors and does not necessarily represent the official views of NINDS or the National Institutes of Health.

  • How to Cite this Article: Ramocki MB, Tavyev YJ, Peters SU. 2010. The MECP2 duplication syndrome. Am J Med Genet Part A 152A:1079–1088.


In this review, we detail the history, molecular diagnosis, epidemiology, and clinical features of the MECP2 duplication syndrome, including considerations for the care of patients with this X-linked neurodevelopmental disorder. MECP2 duplication syndrome is 100% penetrant in affected males and is associated with infantile hypotonia, severe to profound mental retardation, autism or autistic features, poor speech development, recurrent infections, epilepsy, progressive spasticity, and, in some cases, developmental regression. Most of the reported cases are inherited, however, de novo cases have been documented. While carrier females have been reported to be unaffected, more recent research demonstrates that despite normal intelligence, female carriers display a range of neuropsychiatric phenotypes that pre-date the birth of an affected son. Given what we know of the syndrome to date, we propose that genetic testing is warranted in cases of males with infantile hypotonia and in cases of boys with mental retardation and autistic features with or without recurrent infections, progressive spasticity, epilepsy, or developmental regression. We discuss recommendations for clinical management and surveillance as well as the need for further clinical, genotype–phenotype, and molecular studies to assist the patients and their families who are affected by this syndrome. © 2010 Wiley-Liss, Inc.